A5066298482- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Systemic Lupus Erythematosus Research
- Polyomavirus and related diseases
- Cytokine Signaling Pathways and Interactions
- Rheumatoid Arthritis Research and Therapies
- Neuroinflammation and Neurodegeneration Mechanisms
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- Systemic Sclerosis and Related Diseases
- Autoimmune and Inflammatory Disorders Research
- Neurogenesis and neuroplasticity mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Mycobacterium research and diagnosis
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- Immune Response and Inflammation
- RNA regulation and disease
- Amyotrophic Lateral Sclerosis Research
- Advanced Neuroimaging Techniques and Applications
- Long-Term Effects of COVID-19
- Prion Diseases and Protein Misfolding
- T-cell and B-cell Immunology
- Skin and Cellular Biology Research
University Hospital of Basel
2014-2024
Ruhr University Bochum
2024
Heinrich Heine University Düsseldorf
2024
St. Josef-Hospital
2024
University of California, San Francisco
2024
University of Basel
2024
Palacký University Olomouc
2024
The University of Sydney
2024
Piedmont HealthCare
2024
Cleveland Clinic
2010-2023
Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and most common cause neurologic disability in young adults. Despite antiinflammatory or immunosuppressive therapy, patients have progressive deterioration that may reflect axonal loss. We conducted pathological studies brain tissues to define changes axons with multiple sclerosis.
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment trials, treatment decision-making. Standardized published in 1996 based on a survey international MS experts provided purely phenotypes data consensus at that time, but imaging biological correlates were lacking. Increased understanding its pathology, coupled with general concern the original descriptors may not adequately reflect more...
Abstract The accepted standard treatment of relapsing multiple sclerosis consists medications for disease symptoms, including acute exacerbations. However, currently there is no therapy that alters the progression physical disability associated with this disease. purpose study was to determine whether interferon beta‐1a could slow progressive, irreversible, neurological sclerosis. Three hundred one patients were randomized into a double‐blinded, placebo‐controlled, multicenter phase I11...
Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared be safe and effective alone when added beta-1a in preliminary studies.We randomly assigned 1171 who, despite had at least one relapse during 12-month period before randomization receive continued combination with 300 mg natalizumab (589 patients) or placebo (582 intravenously every 4 weeks for up 116 weeks....
Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most lesions multiple are not remyelinated, enhancement remyelination a possible therapeutic strategy could perhaps be achieved with transplantation oligodendrocyte-producing cells into lesions. We investigated frequency distribution configuration oligodendrocytes in chronic to determine whether these factors limit remyelination.
Abstract Objective Degeneration of chronically demyelinated axons is a major cause irreversible neurological disability in multiple sclerosis (MS) patients. Development neuroprotective therapies will require elucidation the molecular mechanisms by which neurons and degenerate. Methods We report ultrastructural changes that support Ca2+‐mediated destruction MS compared expression levels 33,000 characterized genes postmortem motor cortex from six control brains matched for age, sex, interval....
<b><i>Background:</i></b> Episodic inflammation in the CNS during early stages of MS results progressive disability years later, presumably due to myelin and axonal injury. MRI demonstrates ongoing disease activity stage, even some patients who are stable clinically. The optimal measure for destructive pathologic process is uncertain, however. <b><i>Methods:</i></b> In this post-hoc study, scans were analyzed from with relapsing participating a placebo-controlled trial interferon β-1a. brain...
Cognitive and motor performance measures are commonly employed in multiple sclerosis (MS) research, particularly when the purpose is to determine efficacy of treatment. The increasing focus new therapies on slowing progression or reversing neurological disability makes utilization sensitive, reproducible, valid essential. Processing speed a basic elemental cognitive function that likely influences downstream processes such as memory. Multiple Sclerosis Outcome Assessments Consortium (MSOAC)...
Abstract Objective To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at all stages of disease, and to identify predictors clinical correlates GM atrophy. Methods MS healthy control subjects were observed over 4 years with standardized magnetic resonance imaging (MRI) neurological examinations. Whole‐brain, GM, white calculated. Subjects categorized by disease status disability progression the significance MRI determined through regression. Results included 17...
Axonal degeneration has been proposed as a cause of irreversible neurological disability in multiple sclerosis (MS) patients. The purpose this study was to quantify axonal loss spinal cord lesions from 5 paralyzed (Expanded Disability Status Scale score > or =7.5) MS patients and determine if number volume correlated with levels the neuronal marker N-acetyl aspartate (NAA). ranged 45 84% averaged 68%. NAA were significantly reduced (>50%) cross sections cords containing lesions. Reduced...
Vascular comorbidity adversely influences health outcomes in several chronic conditions. comorbidities are common multiple sclerosis (MS), but their impact on disease severity is unknown. may contribute to the poorly understood heterogeneity MS severity. Treatment of vascular represent an avenue for treating MS.
<b><i>Background:</i></b> Interferon β-1a (IFNβ-1a, Avonex) is efficacious in relapsing forms of MS. Studies other IFNβ preparations secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNβ-1a slowed disease progression SP-MS. <b><i>Methods:</i></b> A total 436 subjects with SPMS and Expanded Disability Status Scale (EDSS) score 3.5 6.5 were randomized receive (60 μg) or placebo by weekly intramuscular injection for 2 years. The primary...
Impaired manual dexterity is a frequently reported disability in people with multiple sclerosis (MS) and increasingly prevalent worsening disease. While various tests patient-reported outcome measures are available, the Nine-Hole Peg Test (NHPT) considered as gold standard measure of most used MS research clinical practice. The Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food Drug Administration (FDA), European Medicines Agency (EMA), National...
In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients with relapsing multiple sclerosis (MS), natalizumab significantly reduced the relapse rate by 68% progression of sustained disability 42% vs placebo. We report effect on MRI measures from AFFIRM study.The number volume gadolinium (Gd)-enhancing, new or enlarging T2-hyperintense, T1-hypointense lesions brain parenchymal fraction were...
The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) includes representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders Stroke (NINDS), academic institutions, industry partners along with persons living multiple sclerosis (MS). One the MSOAC goals is acceptance qualification by regulators performance outcomes that are highly reliable valid, practical, cost-effective, meaningful in...
<h3>Background:</h3> Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment patients multiple sclerosis (MS) despite lack data regarding the safety interruption, rate and severity MS disease activity return after or alternative strategies. <h3>Objectives:</h3> To determine effects interruption on clinical MRI measures in relapsing MS. <h3>Methods:</h3> Clinical relapses gadolinium-enhanced (Gd+)...
The need for more robust outcomes in multiple sclerosis (MS) clinical trials has been a main priority of the field decades. Dissatisfaction with existing measures led to several consensus meetings and initiatives over past few decades hopes defining gaining acceptance that are valid, reliable, sensitive change progression, most importantly, relevant those living MS. Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed this purpose.The objective paper is describe results MSOAC...
To characterize whole-brain atrophy in relapsing-remitting MS (RRMS) patients over an 8-year period. The specific goals of this study were to determine if brain is related subsequent disability status and identify MRI correlates progression.A follow-up was conducted reassess from a phase III trial interferon beta-1a (IFNbeta-1a) 8 years after randomization. Clinical data 172 followed 2 the original used as baseline data. Follow-up obtained on 160 patients, including 134 with examinations....
Abstract This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment future controlled trials. herein follow extensive deliberation data analysis during 2.5 years. General principles desirable measurement attributes were used to assess alternative techniques scales. On basis of existing multiple sclerosis (MS)...
<i>Background:</i> IV methylprednisolone (IVMP) has been used to treat relapses in patients with relapsing-remitting (RR) MS, but its effect on disease progression is not known. Furthermore, there are no data the impact of IVMP T1 black holes or whole-brain atrophy. <i>Objective:</i> To determine MRI measures destructive pathology RR-MS and secondarily disability RR-MS. <i>Methods:</i> The authors conducted a randomized, controlled, single-blind, phase II clinical trial Eighty-eight baseline...
To determine if progressive brain atrophy could be detected over 1- and 2-year intervals in relapsing MS, based on annual MR studies from the Multiple Sclerosis Collaborative Research Group (MSCRG) trial of interferon beta-1a (Avonex).All subjects had mild to moderate disability, with baseline expanded disability status scores ranging 1.0 3.5, at least two relapses 3 years before study entry. Atrophy measures included third lateral ventricle width, corpus callosum area.Significant increases...